Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates.

Abstract

Osteonecrosis of the jaw (ONJ) is a rare but very serious disease that can affect both jaws. It is defined as exposed bone in the maxillofacial region that does not heal within 8 weeks after a health care provider identification. ONJ can occur spontaneously or can be due to drugs like bisphosphonates (BPS) and anti-RANK agents, in patients with no history of external radiation therapy in the craniofacial region. Although in phase 3 trials of tyrosine kinase inhibitors (TKIs) used in thyroid cancer (TC) the ONJ was not reported among the most common side effects, several papers reported the association between ONJ and TKIs, both when they are used alone and in combination with a bisphosphonate. The appearance of an ONJ in a patient with metastatic radio-iodine refractory differentiated TC, treated with zoledronic acid and sorafenib, has put us in front of an important clinical challenge: when a ONJ occurred during TKIs treatment, it really worsens the patients' quality of life. We should consider that in the case of ONJ a TKI discontinuation becomes necessary, and this could lead to a progression of neoplastic disease. The most important aim of this review is to aware the endocrinologists/oncologists dealing with TC to pay attention to this possible side effect of BPS and TKIs, especially when they are used in association. To significantly reduced the risk of ONJ, both preventive measures before initiating not only antiresorptive therapy but also antiangiogenic agents, and regular dental examinations during the treatment should always be proposed.

• Authors: L Lorusso, L Pieruzzi, M Gabriele, M Nisi, D Viola, E Molinaro, V Bottici, R Elisei, L Agate
• Journal: Journal of endocrinological investigation (J Endocrinol Invest) Vol. 44 Issue 12 Pg. 2557-2566 (Dec 2021) ISSN: 1720-8386 [Electronic] Italy
• PMID: 34291429 (Publication Type: Journal Article, Review)
• Copyright: © 2021. The Author(s).

Chemical References

• Antineoplastic Agents
• Bone Density Conservation Agents
• Protein Kinase Inhibitors

Topics

• Antineoplastic Agents (administration & dosage, adverse effects)
• Bone Density Conservation Agents (administration & dosage, adverse effects)
• Humans
• Jaw Diseases (chemically induced, prevention & control)
• Osteonecrosis (chemically induced, prevention & control)
• Protein Kinase Inhibitors (administration & dosage, adverse effects)
• Risk Adjustment (methods)
• Thyroid Neoplasms (drug therapy)